TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  GlobeNewswire Inc.

TLX 11-DAY DEADLINE ALERT: Hagens Berman Urges Telix (TLX) Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Hagens Berman
TLX 11-DAY DEADLINE ALERT: Hagens Berman Urges Telix (TLX) Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain

Hagens Berman is urging Telix Pharmaceuticals investors to act by January 9, 2026, as lead plaintiff deadline approaches in a securities class action lawsuit. The lawsuit alleges the company materially overstated therapeutic candidate progress and concealed supply chain/manufacturing deficiencies. Regulatory setbacks include an SEC subpoena regarding drug development disclosures and an FDA Complete Response Letter rejecting the Zircaix application due to Chemistry, Manufacturing, and Controls deficiencies, triggering a 21% stock decline.

Insights
NRGD   neutral

Proposed a modular approach to AI agents, focusing on specialized, discrete task performance

TLX   negative

Company faces dual regulatory investigations (SEC subpoena and FDA CRL), alleged material misstatements about drug development progress, concealed supply chain deficiencies, and significant stock decline (21% drop), resulting in securities fraud litigation and investor losses.

Keywords
#securities class action #regulatory failure #SEC subpoena #FDA Complete Response Letter #CMC deficiencies #supply chain #manufacturing #investor losses #lead plaintiff deadline

Tickers
TLX
← Prev: Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale